Systems and methods for enhanced SCODA

Patent metadata

Field	Value
Publication number	US-10400266-B2
Application number	US-201615171027-A
Country	US
Kind code	B2
Filing date	Jun 2, 2016
Priority date	May 20, 2011
Publication date	Sep 3, 2019
Grant date	Sep 3, 2019

Abstract

Methods and apparatus for separating, concentrating and/or detecting molecules based on differences in binding affinity to a probe are provided. The molecules may be differentially modified. The molecules may be differentially methylated nucleic acids. The methods can be used in fields such as epigenetics or oncology to selectively concentrate or detect the presence of specific biomolecules or differentially modified biomolecules, to provide diagnostics for disorders such as fetal genetic disorders, to detect biomarkers in cancer, organ failure, disease states, infection or the like.

First claim

What is claimed is:

1. A method for concentrating a molecule of interest from a biological sample, the method comprising the steps of:
obtaining a biological sample from a subject;
loading the sample on an affinity matrix comprising an immobilized affinity agent that has a first binding affinity for the molecule of interest and a second binding affinity for at least some of the other molecules in the biological sample, wherein the first binding affinity is higher than the second binding affinity; and
conducting affinity SCODA to selectively concentrate the molecule of interest into a focus spot, wherein the concentration of the molecule of interest in the focus spot is increased relative to the concentration of the other molecules in the biological sample, and wherein the molecule of interest comprises a first molecule that is differentially modified as compared with a second molecule in the biological sample comprising the same sequence as the first molecule.

2. A method as defined in claim 1 , wherein the molecule of interest comprises a biomarker.

3. A method as defined in claim 2 comprising detecting the presence of the biomarker in the focus spot by using PCR, DNA sequencing, digital PCR, or fluorescence detection.

4. A method as defined in claim 2 , wherein the immobilized probe has a binding affinity for a biomarker known to be an indicator of the presence of organ failure, a pathogen, or infection.

5. A method as defined in claim 1 , wherein the molecule of interest comprises a first molecule that is differentially methylated as compared with a second molecule in the biological sample.

6. A method as defined in claim 1 , wherein the immobilized probe comprises an oligonucleotide, and wherein the molecule of interest comprises a gene having a sequence that is at least partially complementary to the immobilized probe.

7. A method as defined in claim 6 , wherein the immobilized probe comprises an oligonucleotide that is complementary to a gene that is implicated in a fetal genetic disorder, the biological sample comprises maternal plasma, and the step of conducting affinity SCODA comprises separating fetal DNA that is differentially methylated from maternal DNA.

8. A method as defined in claim 7 , comprising selectively concentrating the fetal DNA into the focus spot and isolating the fetal DNA.

9. A method as defined in claim 8 , comprising analyzing the fetal DNA by qPCR, DNA sequencing, or fluorescent detection to count the number of copies of each chromosome in the fetal DNA.

10. A method as defined in claim 9 , wherein the data obtained by counting the number of copies of each chromosome in the fetal DNA is used to determine whether there are an abnormal number of chromosomes present in the fetal DNA.

11. A method as defined in claim 7 , wherein the fetal DNA that is separated from the maternal DNA comprises the same sequence as the maternal DNA from which the fetal DNA is separated.

12. A method as defined in claim 1 , wherein the molecule of interest comprises a differentially methylated form of a gene of interest.

13. A method as defined in claim 12 , wherein the immobilized probe comprises an oligonucleotide probe with a sequence that is complementary to at least a portion of the gene of interest.

14. A method as defined in claim 6 , wherein the immobilized probe is complementary to a gene that is implicated in cancer, and wherein the presence of a differentially modified form of the gene indicates a risk that at least some cells in the sample are cancerous or precancerous.

15. A method as defined in claim 14 , wherein the differentially modified form of the gene of interest comprises a differentially methylated form of the gene of interest.

16. A method as defined in claim 15 , wherein the differentially methylated form of the gene of interest comprises the same sequence as the gene of interest.

Assignees

• Univ British Columbia

Inventors

• Marziali Andrea
• Pel Joel
• Thompson Jason Donald
• Shibahara Gosuke

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/689

  related to pregnancy or the gonads · CPC title

• G01N2800/385

  Congenital anomalies · CPC title

• G01N33/543

  with an insoluble carrier for immobilising immunochemicals · CPC title

• G01N33/5308

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title